| # | Title | Journal | Year | Citations |
|---|
| 1 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) | Autophagy | 2016 | 4,701 |
| 2 | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Lancet, The | 2018 | 3,542 |
| 3 | Guidelines for the use and interpretation of assays for monitoring autophagy | Autophagy | 2012 | 3,122 |
| 4 | p53 in health and disease | Nature Reviews Molecular Cell Biology | 2007 | 2,004 |
| 5 | Crypt stem cells as the cells-of-origin of intestinal cancer | Nature | 2009 | 1,883 |
| 6 | ESPEN guidelines on nutrition in cancer patients | Clinical Nutrition | 2017 | 1,855 |
| 7 | Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial | Lancet, The | 2016 | 1,570 |
| 8 | The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs | Nature Cell Biology | 2009 | 1,547 |
| 9 | Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial | Lancet, The | 2019 | 1,333 |
| 10 | Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome | New England Journal of Medicine | 2013 | 1,258 |
| 11 | ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1 | Lancet, The | 1896 | 1,151 |
| 12 | The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer | Advances in Cancer Research | 2010 | 980 |
| 13 | Coordinating ERK/MAPK signalling through scaffolds and inhibitors | Nature Reviews Molecular Cell Biology | 2005 | 941 |
| 14 | Intestinal Tumorigenesis Initiated by Dedifferentiation and Acquisition of Stem-Cell-like Properties | Cell | 2013 | 889 |
| 15 | Cytoplasmic chromatin triggers inflammation in senescence and cancer | Nature | 2017 | 851 |
| 16 | Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis | Nature | 1986 | 846 |
| 17 | Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP | Nature | 1999 | 808 |
| 18 | Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study | British Journal of Cancer | 2001 | 790 |
| 19 | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial | Lancet Oncology, The | 2015 | 762 |
| 20 | Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors | Cell | 1993 | 757 |
| 21 | A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal | Modern Pathology | 2018 | 739 |
| 22 | Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial | Lancet, The | 2019 | 697 |
| 23 | Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial | Journal of Clinical Oncology | 2020 | 683 |
| 24 | Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial | Nature Medicine | 2018 | 649 |
| 25 | ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES. | Lancet, The | 1896 | 625 |
| 26 | Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial | Lancet, The | 2020 | 603 |
| 27 | Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial | Lancet Oncology, The | 2016 | 594 |
| 28 | Mitochondrial tumour suppressors: a genetic and biochemical update | Nature Reviews Cancer | 2005 | 585 |
| 29 | Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials | BMC Cancer | 2010 | 560 |
| 30 | Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas | Nature | 1984 | 550 |
| 31 | Localized production of TGF-β mRNA in tumour promoter-stimulated mouse epidermis | Nature | 1988 | 549 |
| 32 | Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer | Proceedings of the National Academy of Sciences of the United States of America | 2010 | 530 |
| 33 | A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence | Nature | 2013 | 517 |
| 34 | Autophagy mediates degradation of nuclear lamina | Nature | 2015 | 510 |
| 35 | Malignant transformation of early passage rodent cells by a single mutated human oncogene | Nature | 1984 | 502 |
| 36 | Actomyosin-Mediated Cellular Tension Drives Increased Tissue Stiffness and β-Catenin Activation to Induce Epidermal Hyperplasia and Tumor Growth | Cancer Cell | 2011 | 477 |
| 37 | Identification and characterization of an inhibitor of haemopoietic stem cell proliferation | Nature | 1990 | 454 |
| 38 | The actin cytoskeleton in cancer cell motility | Clinical and Experimental Metastasis | 2009 | 454 |
| 39 | Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial | Lancet Oncology, The | 2020 | 450 |
| 40 | Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial | Lancet, The | 2017 | 448 |
| 41 | Integrins: masters and slaves of endocytic transport | Nature Reviews Molecular Cell Biology | 2009 | 443 |
| 42 | Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase | Nature | 2011 | 433 |
| 43 | Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors | Nature Medicine | 2009 | 428 |
| 44 | Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene | Nature | 1983 | 427 |
| 45 | Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial | Lancet Oncology, The | 2017 | 415 |
| 46 | p53 and its mutants in tumor cell migration and invasion | Journal of Cell Biology | 2011 | 411 |
| 47 | The Transcription Factor AP-1 Is Required for EGF-induced Activation of Rho-like GTPases, Cytoskeletal Rearrangements, Motility, and In Vitro Invasion of A431 Cells | Journal of Cell Biology | 1998 | 402 |
| 48 | Rho-associated coiled-coil containing kinases (ROCK) | Small GTPases | 2014 | 396 |
| 49 | Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial | Lancet Oncology, The | 2014 | 392 |
| 50 | A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers | New England Journal of Medicine | 2013 | 384 |
